Neuberger Berman Group’s aTyr Pharma ATYR Stock Holding History

Neuberger Berman Group’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,743	Closed	-$17K	–	2416
2026 Q1	$17K	Buy	21,743 +1,289	+6%	+$1.09K	﹤0.01%	2151
2025 Q4	$16K	Buy	+20,454	New	+$16.8K	﹤0.01%	2100

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group's ATYR Position: Q2 2026 in Review

Neuberger Berman Group sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 21,743 shares — an estimated $17K sold.

Neuberger Berman Group first reported a position in ATYR in Q4 2025 and held it in 2 quarters. The position peaked at $17K in Q1 2026. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Neuberger Berman Group reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
Neuberger Berman Group sold 21,743 aTyr Pharma shares in Q2 2026, an estimated $17K.
Neuberger Berman Group first reported a position in aTyr Pharma in Q4 2025 and held it in 2 quarters.
Neuberger Berman Group's aTyr Pharma position peaked at $17K in Q1 2026.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.